204 related articles for article (PubMed ID: 15308953)
1. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion.
Hagan H; Thiede H; Des Jarlais DC
Epidemiology; 2004 Sep; 15(5):543-9. PubMed ID: 15308953
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention.
Artenie AA; Roy É; Zang G; Jutras-Aswad D; Bamvita JM; Puzhko S; Daniel M; Bruneau J
Int J Drug Policy; 2015 Oct; 26(10):970-5. PubMed ID: 26005038
[TBL] [Abstract][Full Text] [Related]
3. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.
Patrick DM; Tyndall MW; Cornelisse PG; Li K; Sherlock CH; Rekart ML; Strathdee SA; Currie SL; Schechter MT; O'Shaughnessy MV
CMAJ; 2001 Oct; 165(7):889-95. PubMed ID: 11599327
[TBL] [Abstract][Full Text] [Related]
4. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities.
Hagan H; Pouget ER; Williams IT; Garfein RL; Strathdee SA; Hudson SM; Latka MH; Ouellet LJ
J Infect Dis; 2010 Feb; 201(3):378-85. PubMed ID: 20053137
[TBL] [Abstract][Full Text] [Related]
5. HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection.
Bravo MJ; Vallejo F; Barrio G; Brugal MT; Molist G; Pulido J; Sordo L; de la Fuente L;
Int J Drug Policy; 2012 Sep; 23(5):415-9. PubMed ID: 22421554
[TBL] [Abstract][Full Text] [Related]
6. Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
Jacka B; Roy É; Høj S; Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Bruneau J
J Viral Hepat; 2019 Dec; 26(12):1413-1422. PubMed ID: 31433888
[TBL] [Abstract][Full Text] [Related]
7. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
Bird SM; Goldberg DJ; Hutchinson SJ
J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
[TBL] [Abstract][Full Text] [Related]
8. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes.
Vallejo F; Barrio G; Brugal MT; Pulido J; Toro C; Sordo L; Espelt A; Bravo MJ;
J Epidemiol Community Health; 2015 Jun; 69(6):599-603. PubMed ID: 25870164
[TBL] [Abstract][Full Text] [Related]
9. Dual sexual and drug-related predictors of hepatitis C incidence among sex workers in a Canadian setting: gaps and opportunities for scale-up of hepatitis C virus prevention, treatment, and care.
Goldenberg SM; Montaner J; Braschel M; Socias E; Guillemi S; Shannon K
Int J Infect Dis; 2017 Feb; 55():31-37. PubMed ID: 28027990
[TBL] [Abstract][Full Text] [Related]
10. High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention.
Puzhko S; Roy É; Jutras-Aswad D; Artenie AA; Fortier E; Zang G; Bruneau J
Int J Drug Policy; 2017 Sep; 47():61-68. PubMed ID: 28666636
[TBL] [Abstract][Full Text] [Related]
11. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience.
Roy E; Boudreau JF; Boivin JF
Drug Alcohol Depend; 2009 Jun; 102(1-3):158-61. PubMed ID: 19251382
[TBL] [Abstract][Full Text] [Related]
13. Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion.
Wilton J; Wong S; Purssell R; Abdia Y; Chong M; Karim ME; MacInnes A; Bartlett SR; Balshaw RF; Gomes T; Yu A; Alvarez M; Dart RC; Krajden M; Buxton JA; Janjua NZ
JAMA Netw Open; 2022 Jan; 5(1):e2143050. PubMed ID: 35019983
[TBL] [Abstract][Full Text] [Related]
14. Sharing of drug preparation equipment as a risk factor for hepatitis C.
Hagan H; Thiede H; Weiss NS; Hopkins SG; Duchin JS; Alexander ER
Am J Public Health; 2001 Jan; 91(1):42-6. PubMed ID: 11189822
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy.
Spada E; Rezza G; Garbuglia AR; Lombardo FL; Zuccaro O; Menniti Ippolito F; Cupellaro E; Capone S; Capobianchi MR; Nicosia A; Cortese R; Folgori A; Mele A;
J Urban Health; 2018 Feb; 95(1):99-110. PubMed ID: 29204843
[TBL] [Abstract][Full Text] [Related]
16. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion.
Beld M; Penning M; van Putten M; van den Hoek A; Damen M; Klein MR; Goudsmit J
Blood; 1999 Aug; 94(4):1183-91. PubMed ID: 10438705
[TBL] [Abstract][Full Text] [Related]
17. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment.
Thorpe LE; Ouellet LJ; Hershow R; Bailey SL; Williams IT; Williamson J; Monterroso ER; Garfein RS
Am J Epidemiol; 2002 Apr; 155(7):645-53. PubMed ID: 11914192
[TBL] [Abstract][Full Text] [Related]
18. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.
Miller CL; Johnston C; Spittal PM; Li K; Laliberté N; Montaner JS; Schechter MT
Hepatology; 2002 Sep; 36(3):737-42. PubMed ID: 12198668
[TBL] [Abstract][Full Text] [Related]
19. [Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the North and East of France].
Bruandet A; Lucidarme D; Decoster A; Ilef D; Harbonnier J; Jacob C; Delamare C; Cyran C; Van Hoenacker AF; Frémaux D; Josse P; Emmanuelli J; Le Strat Y; Filoche B; Desenclos JC
Rev Epidemiol Sante Publique; 2006 Jul; 54 Spec No 1():1S15-1S22. PubMed ID: 17073126
[TBL] [Abstract][Full Text] [Related]
20. HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination.
Valencia La Rosa J; Ryan P; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Moreno S
PLoS One; 2018; 13(10):e0204795. PubMed ID: 30281616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
